Investigation Report on China Sildenafil Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Sildenafil Market, 2009-2018. There are hundreds of millions of males suffering from sexual dysfunction in the world, of which over 50 million are in China. Statistics indicates that more than 60% of males aged above 35 in China have sexual dysfunction of different degrees. About 50% of the causes of erectile dysfunction are organic, and 30% are psychological while 20% of them are organic and psychological at the same time. Erectile dysfunction can have severe psychological consequences as it can be tied to relationship difficulties and masculine self-image generally. Consequently many pharmaceutical enterprises are very concerned about male sexual dysfunction drug market.

Sildenafil, developed by Pfizer Co., Ltd., was originally developed as a phosphodiesterase type 5 inhibitor (PDE5 inhibitor) to treat cardiovascular diseases. However, the medicine did not avail against the disease. In April 1991, the clinical research of sildenafil officially failed, but a side effect in the report attracted the researchers' attention. They found that patients were unwilling to return the remaining medication after the trial. Through further investigation researchers discovered that the medication can improve the patients' sexual life. Under the permission of Pfizer's top management, experiment about sildenafil's effect on penile corpus cavernosum smooth muscle was carried out. The medication (sildenafil produced by Pfizer with the trade name "Viagra") was approved to the market by FDA on March 27, 1998, which soon became a world-famous product of Pfizer Co., Ltd.
Besides erectile dysfunction, sildenafil is also useful for the prevention and treatment of high-altitude pulmonary edema and altitude sickness.

The global sales revenue of Viagra reached USD 2.05 billion in 2012. Indications patent owned by Pfizer expires in 2014. Viagra entered China in 1998. According to investigation on sample hospitals in China, the sales revenue of Viagra keeps rising steadily without sharp increase. CRI reckons that most of its sales revenue in China is from drug stores instead of hospitals since Viagra can be easily bought in many drug stores without prescription though it is a prescription drug in China. For Viagra is an important medication in treatment of sexual dysfunction in China, many domestic enterprises started to produce its generic drug. A sildenafil generic drug produced by certain Chinese pharmaceutical enterprise is expected to appear on the market in the third quarter of 2014. Sildenafil produced by other enterprises will be launched soon in succession. Price of Viagra in China may be reduced as the generic drugs enter the market. However, the price reduction will not prevent Pfizer's market share from decreasing since prices of homemade generic drugs will be even lower. The number of sexual dysfunction patients will continue to rise in the next few years as economy develops and lifestyle changes as well as stress increases in China. Furthermore, new indications of sildenafil will appear. Market size of sildenafil in China will therefore continue to grow.

Through this report, the readers can acquire the following information:
-Incidence of Male Sexual Dysfunction in China
-Sales Price of Sildenafil in China Hospital Market
-R&D Schedule of Sildenafil Generic Drug in China
-Market Overview of Sildenafil in China

The following enterprises and people are recommended to purchase this report:
-Sildenafil Manufacturers
-Medical Institutions
-Investors /Research Agencies Focusing on Male Sexual Dysfunction Drug Market

To view the table of contents and know more details please visit Investigation Report on China Sildenafil Market, 2009-2018.